Healio reports that the French National Research Institute for Sustainable Development reported results from a study that children of women who used tenofovir disoproxil fumarate (TDF), to prevent transmission of hepatitis B to their children did not have lower bone mineral density compared with children who were exposed to placebo. The findings from the randomized controlled trial were published in Clinical Infectious Diseases.

Lead Research/Investigator

Gonzague Jourdain, MD, PhD

Source: www.healio.com

Pin It on Pinterest